leadf
logo-loader
viewLexaria Bioscience Corp.

Lexaria Bioscience trumpets its slate of DehydraTECH licensing agreements

The company has 9 corporate licensees with 11 licenses developing unique products using its absorption technology

Placeholder
DehydraTECH helps nutrients and pharmaceutical ingredients get absorbed faster and more effectively by the body

Lexaria Bioscience Corp (CSE:LXX) (OTCMKTS:LXRP) has signed eleven licensing agreements for its DehydraTECH drug absorption platform thus far in 2019, the company told shareholders Tuesday.

Broadly, DehydraTECH helps nutrients and pharmaceutical ingredients get absorbed faster and more effectively by the body.

Lexaria’s licensees are using it to create things like cannabis edibles, CBD beverages and oral nicotine products.

For instance, Lexaria is working with Hill Street Beverage Company Inc (CVE:BEER) using DehydraTECH to create THC and CBD powder, and Altria Ventures is targeting a reduced-risk oral nicotine option.

READ: Lexaria Bioscience, Hill Street Beverage sign 10-year joint manufacturing partnership for DehydraTec products

All told, Lexaria has 9 corporate licensees with 11 licensing agreements developing unique products.

CEO Chris Bunka said: "The first half of 2019 delivered a period of unprecedented achievements for Lexaria. We signed more license agreements than ever before in our company’s history, many of which were larger in scope than anything previous.”

The company expects explosive revenue growth as its client commence operations beginning in late 2019. It expects new licensing agreements to continue rolling in as demand for DehydraTECH continues.

There’s promising data to pair with that confidence. In one previously announced animal study, Lexaria’s formations delivered 20 times more CBD into brain tissue and achieved peak blood levels of nine times greater than generic industry formations.

The company's stock fell 3.4% Tuesday to C$0.86 on the CSE and 6.5% to US$0.65 on OTC Markets.

Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com

Follow him on Twitter @andrew_kessel

Quick facts: Lexaria Bioscience Corp.

Price: 0.245 CAD

CSE:LXX
Market: CSE
Market Cap: $22.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexaria Bioscience Corp. named herein, including the promotion by the Company of Lexaria Bioscience Corp. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lexaria receives ethics board ok to launch human study with DehydraTech for...

Lexaria Bioscience (CSE: LXX-OTCQX: LXRP) CEO Chris Bunka joined Steve Darling from Proactive with news the company has received ethics board approval to conduct a pilot human pharmacokinetic exploratory study of antiviral drugs that have previously been studied against other coronavirus...

4 weeks, 1 day ago

2 min read